EUVIMEDEUVIMED entdecken
Crossref

Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis

Takuya Oguma iD, Kohei Jino, Kenji Nakahara, Hidetsugu Asada, Kouki Fuchino, Kotaro Nagatani, Kensuke Kouki, Ryuji Okamoto, Nozomi Takai, Ken Koda, Sayaka Fujita, Yusuke Sekiguchi und 7 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Takuya Oguma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Hauptthemen laut MEDLINE: Antipsychotic Agents, Receptor, Serotonin, 5-HT2A, Psychotic Disorders, Serotonin 5-HT2 Receptor Agonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychosis is a distressing symptom commonly occurring in people with dementia. To treat Parkinson's disease psychosis, pimavanserin (1), a 5-HT2A receptor inverse agonist having minimal 5-HT2C receptor affinity and no dopamine D2 receptor affinity, was approved in the United States, but not for dementia-related psychosis due to limited efficacy issues. Herein, we report on the identification of a potent and dual 5-HT2A and 5-HT2C receptor inverse agonist 8 having minimal hERG inhibition, after having demonstrated the involvement of both 5-HT2A and 5-HT2C receptors to deliver antipsychotic efficacy in an MK-801-induced locomotor model and having conducted 5-HT2A and 5-HT2C occupancy studies including a surrogate method. The introduction of a spirocyclopropyl group boosting 5-HT2C affinity in 1 followed by further optimization to control lipophilicity resulted in balanced dual potency and metabolic stability, and mitigating hERG inhibition led to 8 that showed significant antipsychotic efficacy due to the involvement of both receptors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsReceptor, Serotonin, 5-HT2APsychotic DisordersSerotonin 5-HT2 Receptor AgonistsReceptor, Serotonin, 5-HT2CDementiaAnimalsHumansStructure-Activity RelationshipMaleDrug Inverse AgonismERG1 Potassium ChannelRatsMicePiperidinesRats, Sprague-DawleyEther-A-Go-Go Potassium ChannelsUrea

Substanzen

Antipsychotic AgentsReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsReceptor, Serotonin, 5-HT2CERG1 Potassium ChannelpimavanserinPiperidinesEther-A-Go-Go Potassium ChannelsUrea

Autor:innen und Institutionen

  • Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Laboratory for Drug Discovery & Disease Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Department of Cell Biology, Graduate School of Medicine, Kyoto University, Sakyo-yu, Kyoto 606-8501, Japan.
  • Laboratory for Bio-Modality Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Laboratory for Drug Discovery & Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.

ORCID-Profile: Takuya Oguma, Ken-Ichi Kusakabe

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Oguma, T., Jino, K., Nakahara, K., Asada, H., Fuchino, K., Nagatani, K., Kouki, K., Okamoto, R., Takai, N., Koda, K., Fujita, S., Sekiguchi, Y., Yasuo, K., Mayumi, K., Abe, A., Imono, M., Horiguchi, N., Iwata, S., & Kusakabe, K. I. (2024). Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01244

Vancouver

Oguma T, Jino K, Nakahara K, Asada H, Fuchino K, Nagatani K, et al. Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01244

BibTeX
@article{Oguma2024,
  author = {Oguma, Takuya and Jino, Kohei and Nakahara, Kenji and Asada, Hidetsugu and Fuchino, Kouki and Nagatani, Kotaro and Kouki, Kensuke and Okamoto, Ryuji and Takai, Nozomi and Koda, Ken and Fujita, Sayaka and Sekiguchi, Yusuke and Yasuo, Kazuya and Mayumi, Kei and Abe, Ayane and Imono, Masaaki and Horiguchi, Naotaka and Iwata, So and Kusakabe, Ken-Ichi},
  title = {Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01244}
}
Kostenlos starten →